Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.55 |
| ▸ | HPGD | P15428 | 2/20 | 0.55 |
| ▸ | TSHR | P16473 | 3/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | USP2 | O75604 | 1/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 4/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.42 |
| ▸ | RAB9A | P51151 | 2/20 | 0.42 |
| ▸ | RNASEH1 | O60930 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.42 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31394853 | 1.00 | LMNA (0.55) | LMNAHPGDTSHRALDH1A1USP2 | |
| SCHEMBL30037690 | 0.87 | ALDH1A1 (0.46) | LMNAHPGDTSHRALDH1A1L3MBTL1 | |
| SCHEMBL25037377 | 0.87 | ALDH1A1 (0.46) | LMNAHPGDTSHRALDH1A1L3MBTL1 | |
| SCHEMBL4326071 | 0.86 | LMNA (0.58) | LMNAHPGDTSHRALDH1A1USP2 | |
| SCHEMBL31082174 | 0.85 | LMNA (0.53) | LMNAHPGDTSHRALDH1A1USP2 | |
| SCHEMBL31329652 | 0.84 | PTPN1 (0.41) | LMNAHPGDTSHRALDH1A1USP2 | |
| SCHEMBL31082164 | 0.83 | HPGD (0.51) | LMNAHPGDTSHRALDH1A1USP2 | |
| SCHEMBL31082276 | 0.81 | LMNA (0.49) | LMNAHPGDTSHRALDH1A1USP2 | |
| SCHEMBL31082479 | 0.77 | CYP11B1 (0.47) | LMNAHPGDTSHRALDH1A1HSD17B10 | |
| SCHEMBL25037121 | 0.77 | NPSR1 (0.43) | ALDH1A1SMN1; SMN2L3MBTL1TDP1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4601746-A1 | TRICYCLIC COMPOUNDS AND THEIR USES | Novartis AG (CH) | 2025-08-20 | — | — | EP | disclosed |
| CN-120077048-A | Tricyclic compounds and uses thereof | 诺华股份有限公司 | 2025-05-30 | — | — | CN | disclosed |
| WO-2025049746-A1 | COMPOSITIONS COMPRISING WERNER SYNDROME HELICASE INHIBITORS AND METHODS OF USING THE SAME | EIKON THERAPEUTICS, INC. (US) | 2025-03-06 | — | — | WO | disclosed |
| US-20240360118-A1 | Bicyclic Compounds and their Uses | NOVARTIS PHARMA AG (CH) | 2024-10-31 | — | — | US | disclosed |
| US-20240245694-A1 | Tricyclic Compounds and their Uses | NOVARTIS PHARMA AG (CH) | 2024-07-25 | — | — | US | disclosed |
| WO-2024079623-A1 | TRICYCLIC COMPOUNDS AND THEIR USES | NOVARTIS AG (CH) | 2024-04-18 | — | — | WO | disclosed |
| EP-4347596-A1 | TRIAZOLO-PYRIMIDINE ANALOGUES FOR TREATING DISEASES CONNECTED TO THE INHIBITON OF WERNER SYNDROME RECQ HELICASE (WRN) | Novartis AG (CH) | 2024-04-10 | — | — | EP | disclosed |
| US-11878973-B2 | Bicyclic compounds and their uses | NOVARTIS AG (CH) | 2024-01-23 | — | — | US | disclosed |
| CN-117425657-A | Triazolo-pyrimidine analogs for the treatment of diseases associated with inhibition of Wonna syndrome RECzochralski enzyme (WRN) | 诺华股份有限公司 | 2024-01-19 | — | — | CN | disclosed |
| US-20230046859-A1 | Bicyclic Compounds and their Uses | NOVARTIS PHARMA AG (CH) | 2023-02-16 | — | — | US | disclosed |
| US-20230046859-A1 | Bicyclic Compounds and their Uses | NOVARTIS PHARMA AG (CH) | 2023-02-16 | — | — | US | disclosed |
| WO-2022249060-A1 | TRIAZOLO-PYRIMIDINE ANALOGUES FOR TREATING DISEASES CONNECTED TO THE INHIBITON OF WERNER SYNDROME RECQ HELICASE (WRN) | NOVARTIS AG (CH) | 2022-12-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240360118-A1 | Bicyclic Compounds and their Uses | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, C1R, F12 | LMNA 1597/4885HPGD 3055/4885TSHR 1331/4885 |
| US-11878973-B2 | Bicyclic compounds and their uses | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, C1R, F12 | LMNA 1597/4885HPGD 3055/4885TSHR 1331/4885 |
| US-20240245694-A1 | Tricyclic Compounds and their Uses | F12, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, C1R | LMNA 1273/4885HPGD 2592/4885TSHR 579/4885 |
| US-20230046859-A1 | Bicyclic Compounds and their Uses | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, C1R, F12 | LMNA 1597/4885HPGD 3055/4885TSHR 1331/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.